

Weina Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3561618/publications.pdf>

Version: 2024-02-01

27
papers

1,091
citations

516710

16
h-index

526287

27
g-index

36
all docs

36
docs citations

36
times ranked

1179
citing authors

#	ARTICLE	IF	CITATIONS
1	A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. <i>Nature Medicine</i> , 2021, 27, 106-114.	30.7	204
2	Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 80-91.	9.1	103
3	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. <i>EBioMedicine</i> , 2020, 62, 103132.	6.1	77
4	Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model. <i>Journal of Virology</i> , 2017, 91, .	3.4	70
5	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2020, 8, 771.	4.4	61
6	A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. <i>Nature Communications</i> , 2021, 12, 6197.	12.8	61
7	Development of Influenza B Universal Vaccine Candidates Using the “Mosaic” Hemagglutinin Approach. <i>Journal of Virology</i> , 2019, 93, .	3.4	53
8	Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. <i>Journal of Clinical Investigation</i> , 2018, 128, 4992-4996.	8.2	51
9	A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. <i>Npj Vaccines</i> , 2019, 4, 31.	6.0	40
10	Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. <i>MBio</i> , 2021, 12, e0190821.	4.1	32
11	An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations. <i>PLoS ONE</i> , 2018, 13, e0194830.	2.5	27
12	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. <i>EClinicalMedicine</i> , 2022, 45, 101323.	7.1	26
13	Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice. <i>Journal of Virology</i> , 2018, 92, .	3.4	24
14	Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans. <i>Journal of Virology</i> , 2019, 93, .	3.4	21
15	Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals. <i>Journal of Virology</i> , 2020, 94, .	3.4	19
16	The Influenza B Virus Hemagglutinin Head Domain Is Less Tolerant to Transposon Mutagenesis than That of the Influenza A Virus. <i>Journal of Virology</i> , 2018, 92, .	3.4	18
17	Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase. <i>Journal of Virology</i> , 2019, 93, .	3.4	18
18	Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts. <i>Npj Vaccines</i> , 2019, 4, 51.	6.0	18

#	ARTICLE	IF	CITATIONS
19	Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Vaccine, 2022, 40, 3621-3632.	3.8	15
20	Combined Intranasal Nanoemulsion and RIG-I Activating RNA Adjuvants Enhance Mucosal, Humoral, and Cellular Immunity to Influenza Virus. Molecular Pharmaceutics, 2021, 18, 679-698.	4.6	14
21	Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. Frontiers in Immunology, 2021, 12, 791764.	4.8	14
22	A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. Molecular Therapy, 2022, 30, 2024-2047.	8.2	14
23	Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. Microbiology Spectrum, 2022, 10, .	3.0	14
24	An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains. Vaccines, 2019, 7, 117.	4.4	12
25	Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	10
26	Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice. Frontiers in Immunology, 2021, 12, 746447.	4.8	9
27	An Egg-Derived Sulfated N-Acetylglucosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines. MBio, 2021, 12, e0083821.	4.1	8